Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Jonathan A. Fletcher, M.D.

Co-Author

This page shows the publications co-authored by Jonathan Fletcher and Adrian Marino Enriquez.
Connection Strength

5.153
  1. BCOR Internal Tandem Duplication in High-grade Uterine Sarcomas. Am J Surg Pathol. 2018 03; 42(3):335-341.
    View in: PubMed
    Score: 0.777
  2. Genome-wide functional screening identifies CDC37 as a crucial HSP90-cofactor for KIT oncogenic expression in gastrointestinal stromal tumors. Oncogene. 2014 Apr 03; 33(14):1872-6.
    View in: PubMed
    Score: 0.554
  3. YWHAE-NUTM2 oncoprotein regulates proliferation and cyclin D1 via RAF/MAPK and Hippo pathways. Oncogenesis. 2021 May 04; 10(5):37.
    View in: PubMed
    Score: 0.242
  4. Relationships between highly recurrent tumor suppressor alterations in 489 leiomyosarcomas. Cancer. 2021 Aug 01; 127(15):2666-2673.
    View in: PubMed
    Score: 0.241
  5. Mesenchymal tumors of the gastrointestinal tract with NTRK rearrangements: a clinicopathological, immunophenotypic, and molecular study of eight cases, emphasizing their distinction from gastrointestinal stromal tumor (GIST). Mod Pathol. 2021 01; 34(1):95-103.
    View in: PubMed
    Score: 0.229
  6. Cyclin D1 is a mediator of gastrointestinal stromal tumor KIT-independence. Oncogene. 2019 09; 38(39):6615-6629.
    View in: PubMed
    Score: 0.214
  7. KIT-Dependent and KIT-Independent Genomic Heterogeneity of Resistance in Gastrointestinal Stromal Tumors - TORC1/2 Inhibition as Salvage Strategy. . 2019 11; 18(11):1985-1996.
    View in: PubMed
    Score: 0.214
  8. Complementary activity of tyrosine kinase inhibitors against secondary kit mutations in imatinib-resistant gastrointestinal stromal tumours. Br J Cancer. 2019 03; 120(6):612-620.
    View in: PubMed
    Score: 0.208
  9. What is New in Gastrointestinal Stromal Tumor? Adv Anat Pathol. 2017 Sep; 24(5):259-267.
    View in: PubMed
    Score: 0.188
  10. MAX inactivation is an early event in GIST development that regulates p16 and cell proliferation. Nat Commun. 2017 03 08; 8:14674.
    View in: PubMed
    Score: 0.182
  11. ALK oncoproteins in atypical inflammatory myofibroblastic tumours: novel RRBP1-ALK fusions in epithelioid inflammatory myofibroblastic sarcoma. J Pathol. 2017 Feb; 241(3):316-323.
    View in: PubMed
    Score: 0.179
  12. Alternate PAX3-FOXO1 oncogenic fusion in biphenotypic sinonasal sarcoma. Genes Chromosomes Cancer. 2016 Jan; 55(1):25-9.
    View in: PubMed
    Score: 0.164
  13. HDACi inhibits liposarcoma via targeting of the MDM2-p53 signaling axis and PTEN, irrespective of p53 mutational status. Oncotarget. 2015 Apr 30; 6(12):10510-20.
    View in: PubMed
    Score: 0.160
  14. CDKN2A/p16 Loss Implicates CDK4 as a Therapeutic Target in Imatinib-Resistant Dermatofibrosarcoma Protuberans. . 2015 Jun; 14(6):1346-53.
    View in: PubMed
    Score: 0.159
  15. Dystrophin is a tumor suppressor in human cancers with myogenic programs. Nat Genet. 2014 Jun; 46(6):601-6.
    View in: PubMed
    Score: 0.149
  16. Thyroid hormone inactivation in gastrointestinal stromal tumors. N Engl J Med. 2014 Apr 03; 370(14):1327-34.
    View in: PubMed
    Score: 0.148
  17. KRAS and KIT Gatekeeper Mutations Confer Polyclonal Primary Imatinib Resistance in GI Stromal Tumors: Relevance of Concomitant Phosphatidylinositol 3-Kinase/AKT Dysregulation. J Clin Oncol. 2015 Aug 01; 33(22):e93-6.
    View in: PubMed
    Score: 0.148
  18. MED12 mutations in leiomyosarcoma and extrauterine leiomyoma. Mod Pathol. 2013 May; 26(5):743-9.
    View in: PubMed
    Score: 0.135
  19. Sorafenib inhibits many kinase mutations associated with drug-resistant gastrointestinal stromal tumors. . 2012 Aug; 11(8):1770-80.
    View in: PubMed
    Score: 0.131
  20. 14-3-3 fusion oncogenes in high-grade endometrial stromal sarcoma. Proc Natl Acad Sci U S A. 2012 Jan 17; 109(3):929-34.
    View in: PubMed
    Score: 0.127
  21. ALK rearrangement in sickle cell trait-associated renal medullary carcinoma. Genes Chromosomes Cancer. 2011 Mar; 50(3):146-53.
    View in: PubMed
    Score: 0.118
  22. Coordinated targeting of CK2 and KIT in gastrointestinal stromal tumours. Br J Cancer. 2020 02; 122(3):372-381.
    View in: PubMed
    Score: 0.055
  23. Phase I Study of Rapid Alternation of Sunitinib and Regorafenib for the Treatment of Tyrosine Kinase Inhibitor Refractory Gastrointestinal Stromal Tumors. Clin Cancer Res. 2019 12 15; 25(24):7287-7293.
    View in: PubMed
    Score: 0.054
  24. Inhibition of Bcl-2 family members sensitizes mesenchymal chondrosarcoma to conventional chemotherapy: report on a novel mesenchymal chondrosarcoma cell line. Lab Invest. 2016 10; 96(10):1128-37.
    View in: PubMed
    Score: 0.044
  25. Inhibitor of Apoptosis Proteins (IAPs) are commonly dysregulated in GIST and can be pharmacologically targeted to enhance the pro-apoptotic activity of imatinib. Oncotarget. 2016 Jul 05; 7(27):41390-41403.
    View in: PubMed
    Score: 0.043
  26. Inhibition of Bcl-2 family members sensitises soft tissue leiomyosarcomas to chemotherapy. Br J Cancer. 2016 05 24; 114(11):1219-26.
    View in: PubMed
    Score: 0.043
  27. ALK-rearranged renal cell carcinomas in children. Genes Chromosomes Cancer. 2016 May; 55(5):442-51.
    View in: PubMed
    Score: 0.042
  28. VCL-ALK renal cell carcinoma in children with sickle-cell trait: the eighth sickle-cell nephropathy? Am J Surg Pathol. 2014 Jun; 38(6):858-63.
    View in: PubMed
    Score: 0.037
  29. Frequent expression of KIT in endometrial stromal sarcoma with YWHAE genetic rearrangement. Mod Pathol. 2014 May; 27(5):751-7.
    View in: PubMed
    Score: 0.036
  30. Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin. J Clin Oncol. 2013 Sep 10; 31(26):3182-90.
    View in: PubMed
    Score: 0.035
  31. Cyclin D1 as a diagnostic immunomarker for endometrial stromal sarcoma with YWHAE-FAM22 rearrangement. Am J Surg Pathol. 2012 Oct; 36(10):1562-70.
    View in: PubMed
    Score: 0.033
  32. The clinicopathologic features of YWHAE-FAM22 endometrial stromal sarcomas: a histologically high-grade and clinically aggressive tumor. Am J Surg Pathol. 2012 May; 36(5):641-53.
    View in: PubMed
    Score: 0.032
  33. Aberrant AKT activation drives well-differentiated liposarcoma. Proc Natl Acad Sci U S A. 2011 Sep 27; 108(39):16386-91.
    View in: PubMed
    Score: 0.031
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.